EUVIMEDSkopri EUVIMED
Crossref

Protein Kinase Inhibitor Alpha Drives Vincristine Resistance in Ewing Sarcoma via cAMP–EPAC Signaling Reprogramming

Xin Zhou iD, Yating Yu, Hao Qiu, Zhongliang Deng iD

Molecular Carcinogenesis · 2026

DOI: 10.1002/mc.70065 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2026. Written by Xin Zhou and 3 co-authors. Institution: Department of Orthopedic Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Major MEDLINE topics: Drug Resistance, Neoplasm, Sarcoma, Ewing, Vincristine, Cyclic AMP. 26 references. Funded by: This study was supported by the Natural Science Foundation of Chongqing, China (Chongqing Science and Technology Bureau project) (Grant No. cstc2021jcyj-msxmX0….

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ewing sarcoma (ES) is an aggressive bone malignancy with poor outcomes for chemotherapy‐resistant patients, yet the mechanisms underlying vincristine resistance remain unclear. Here, we identify protein kinase inhibitor alpha (PKIA) as a critical driver of chemoresistance through cAMP–EPAC signaling reprogramming. Transcriptomic analysis of vincristine‐resistant ES cells revealed PKIA upregulation, which correlated with poor survival in clinical cohorts (HR = 2.14, p < 0.001). Mechanistically, PKIA overexpression elevated intracellular cAMP levels but suppressed PKA activity, instead activating the noncanonical EPAC–Rap1–ERK pathway to promote drug efflux and survival. Pharmacological inhibition of EPAC with ESI‐09 reversed resistance (IC~50~ reduction: 52%, p < 0.01), while PKIA knockdown restored vincristine sensitivity in xenografts. Strikingly, PKIA exhibited a dual role, with low expression in primary ES (potentially tumor‐suppressive) and high expression in resistant/metastatic tumors (prosurvival), mirroring observations in prostate and hepatocellular cancers. Our work establishes PKIA as a therapeutic vulnerability and supports targeting the cAMP–EPAC axis to overcome chemoresistance in high‐risk ES.

Subjects

MeSH terms (MEDLINE)

Drug Resistance, NeoplasmSarcoma, EwingVincristineCyclic AMPGuanine Nucleotide Exchange FactorsBone NeoplasmsHumansAnimalsMiceSignal TransductionXenograft Model Antitumor AssaysCell Line, TumorGene Expression Regulation, NeoplasticProtein Kinase Inhibitors

Author keywords

EPAC1Ewing sarcomaPKIAcAMP signalingresistancevincristine

Substances

VincristineCyclic AMPGuanine Nucleotide Exchange FactorsRAPGEF3 protein, humanProtein Kinase Inhibitors

Authors and institutions

  • Department of Orthopedic Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Orthopedic Surgery, Chongqing University Jiangjin Hospital, Centre Hospital of Jiangjin District, Chongqing, China.

ORCID profiles: Xin Zhou, Zhongliang Deng

Funding

  • This study was supported by the Natural Science Foundation of Chongqing, China (Chongqing Science and Technology Bureau project) (Grant No. cstc2021jcyj-msxmX0…

Cite

APA

Zhou, X., Yu, Y., Qiu, H., & Deng, Z. (2026). Protein Kinase Inhibitor Alpha Drives Vincristine Resistance in Ewing Sarcoma via cAMP–EPAC Signaling Reprogramming. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70065

Vancouver

Zhou X, Yu Y, Qiu H, Deng Z. Protein Kinase Inhibitor Alpha Drives Vincristine Resistance in Ewing Sarcoma via cAMP–EPAC Signaling Reprogramming. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70065

BibTeX
@article{Zhou2026,
  author = {Zhou, Xin and Yu, Yating and Qiu, Hao and Deng, Zhongliang},
  title = {Protein Kinase Inhibitor Alpha Drives Vincristine Resistance in Ewing Sarcoma via cAMP–EPAC Signaling Reprogramming},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  doi = {10.1002/mc.70065}
}
Start for free →